arrow
L

Loreto Boix

university of barcelona
H指数:32
被引数:5,779
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

miR-122 Deficiency in Mice Enhances Regeneration in Healthy Liver but Drives Pathological Repair and Functional Decline in Fibrotic Liver

小鼠中miR-122缺乏在健康肝脏中促进再生,但在纤维化肝脏中驱动病理性修复和功能下降。

2026-03-310
OAAI
Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial)

临床试验:二线治疗中,在瑞戈非尼基础上早期加用纳武利尤单抗治疗肝细胞癌患者(GOING试验)

2026-02-230
OAAI
Association of Epigenetic Aging Biomarkers With Risk of MASLD-Related HCC

表观遗传衰老生物标志物与MASLD相关HCC风险的关系

2025-11-290
PRE
Polymeric nanoparticles for liver-targeted pituitary tumor-transforming gene 1 silencing in rats with chronic liver disease

用于慢性肝病大鼠肝脏靶向性垂体肿瘤转化基因1沉默的聚合物纳米粒

2025-09-250
OAAI
Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells
2024-04-091
OAAI
Metabolic liver cancer: associations of rare and common germline variants in one-carbon metabolism and DNA methylation genes
2023-06-273
PRE
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs

索拉非尼早期腹泻作为考虑向二线药物早期迁移的标志

2021-07-061
OAAI
Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity
2021-05-2815
OAAI
Bespoken Nanoceria: An Effective Treatment in Experimental Hepatocellular Carcinoma
2020-10-1440
OAAI